Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.32
40.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Bharat Immunologicals and Biologicals Corporation Ltd
Bharat Immunologicals and Biologicals Corporation Ltd
Income from Continuing Operations
Bharat Immunologicals and Biologicals Corporation Ltd
Income from Continuing Operations Peer Comparison
526139
HESTERBIO
BIOCON
PANACEABIO
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
|
Income from Continuing Operations
-₹184.8m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Transgene Biotek Ltd
BSE:526139
|
Income from Continuing Operations
-₹3.2m
|
CAGR 3-Years
69%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Z
|
Zenotech Laboratories Ltd
BSE:532039
|
Income from Continuing Operations
₹81.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Hester Biosciences Ltd
NSE:HESTERBIO
|
Income from Continuing Operations
₹262.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Biocon Ltd
NSE:BIOCON
|
Income from Continuing Operations
₹18.7B
|
CAGR 3-Years
36%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Panacea Biotec Ltd
NSE:PANACEABIO
|
Income from Continuing Operations
-₹283.6m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Bharat Immunologicals and Biologicals Corporation Ltd's Income from Continuing Operations?
Income from Continuing Operations
-184.8m
INR
Based on the financial report for Sep 30, 2023, Bharat Immunologicals and Biologicals Corporation Ltd's Income from Continuing Operations amounts to -184.8m INR.
What is Bharat Immunologicals and Biologicals Corporation Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-32%
Over the last year, the Income from Continuing Operations growth was -97%. The average annual Income from Continuing Operations growth rates for Bharat Immunologicals and Biologicals Corporation Ltd have been -79% over the past three years , -32% over the past five years .
You don't have any saved screeners yet
